Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘immatics’

Divvying up the ASCO spoils

This is our first Preview from the ASCO 2025 annual meeting. It offers an initial analysis of a selection of the recently released titles, examining emerging trends in modalities and therapeutic approaches before detailed data are presented.

We highlight notable agents across different categories, track shifts in the competitive landscape, and consider what these selections might signal about the direction of oncology drug development.

While we’re working with limited information at this stage, certain patterns are already becoming clear…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Up and coming cell therapy companies to watch out for

Is the early stage cell therapy landscape bleak or promising these days?  Perhaps it depends on which angle you look at the question.

Originally, I had planned to cover five preclinical cell therapy companies we hadn’t covered before, although this ended up as six with five intriguing ones, one I’m not a fan of, plus some additional really intriguing academic research in preclinical development, which may have some broader clinical applications many may have not realised yet.

We also highlight some emerging trends in this niche as early stage companies learn from what has gone before and begin to adapt their pipelines to address the challenges rather than merely be yet another me-too CD19 CAR whatever.

This inevitably means the emergence of new targets, modalities, technologies, and approaches…

To read our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Are gamma delta T cells ready yet for prime time?

Not in San Diego: We took a close look at the potential for targeting gamma delta (𝞬𝝳) T cells early last year in an extended mini-series looking at the landscape including some of the early companies leading the way in this niche.

Since then there’s been a raft of company related announcements and collaborations in recent months, highlighting the ongoing interest in this field.

In this post, it’s time to revisit the original landscape (link), as well as explore how well some of the biotech companies who are active in this space are navigating the R&D roller coaster.

We will also be discussing recent data presented at the AACR20 virtual meetings.

So what did we learn about gamma delta T Cell therapies at AACR20 – who stands out from the increasingly crowded pack?

To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the AACR meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Dracarys! How T cell therapy is like Game of Thrones

If you want to meet a believer in the potential of cellular therapy to treat cancer, then look no further than Dr Cassian Yee.

Dr Yee is Director of Solid tumour Cell Therapy at the University of Texas MD Anderson Center in Houston and a Professor in the Departments of Melanoma Medical Oncology and Immunology.

He’s a pioneer in the development of endogeneous T cell therapy (ETC) that uses the peripheral blood as a source of antigen-specific T cells.

If the cells in the immune system are like the participants in “Game of Thrones” then Dr Yee’s eponymous car number plate and Twitter handle (@tcellsrus) strongly declares his allegiance.

He’s also co-founder of Immatics US, a company jointly founded back in 2015 by Immatics GmBH in Tubingen and MD Anderson, to commercialize next generation adoptive cellular therapy (ACT). The US venture secured $60M of first round funding, including $40M of funding from Immatics.

Dr Yee is not someone we’ve heard a lot from on the conference circuit in recent years, so it was a pleasure to catch up with him in person at the recent @C_IMT annual meeting in Mainz.

To learn more and get a heads up on our latest oncology insights and thought leader interviews, subscribers can log-in or you can click to gain access to BSB Premium Content.

 

This content is restricted to subscribers

ECC Vienna Preview 1 Late Breaking Abstracts

A decade or so ago, the annual conferences for the European Congress of Clinical Oncologists (ECCO) and European Society of Medical Oncologists (ESMO) were considered convenient dumping grounds for negative or failed trials. This was largely because they received much less attention than their big brother, the American Society of Clinical Oncology (ASCO).

In the last few years, this trend has shifted with excellent clincial and scientific data being presented at both meetings – they alternate as hosts each year – under the European Cancer Congress (ECC) umbrella.

Just to confuse a global audience long used to referring to the meetings as ESMO and ECCO, while the logical Twitter hashtag might appear to be #ESMO14 and #ECCO15, respectively, based on the standard nomenclature of conference acronym followed by the year, the vagaries of European politics mean we end up with… #ECC2015.

It will be interesting to see how they compete for attention because this hashtag signal will be dirty (more than one usage) and noisy (many disparate voices) with the European Curling Championship, a European Cheerleader Convention and another on e-cigarettes and vaping, all seemingly using the same moniker!

 

Still, what many readers are really eager to learn though, is this a great, middling, or poor year for exciting new data in the field of cancer research and what can we expect to hear about in Vienna later this month?

To learn more insights on this intriguing topic, subscribers can log-in or you can purchase access to BSB Premium Content. 

This content is restricted to subscribers

error: Content is protected !!